US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

0.573
-0.014-2.33%

Trading Feb 27 09:50 ET

146.70MMarket Cap-3.43P/E (TTM)

Adaptimmune Therapeutics Stock Forum

101674396

Feb 21 03:09

$Adaptimmune Therapeutics (ADAP.US)$ .. Any news ?

101674396

Jan 27 08:10

$Adaptimmune Therapeutics (ADAP.US)$ .. once open will turn to red!!

Spr0ut

Jan 14 18:35

$Adaptimmune Therapeutics (ADAP.US)$ what's with the RSI??

Jaguar8

Jan 13 07:08

NEWS

$Adaptimmune Therapeutics (ADAP.US)$
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Monday, 13th January at 8:00 am
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets
Adaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the
Wuxi Global Forum ...

101674396

Dec 31, 2024 07:39

$Adaptimmune Therapeutics (ADAP.US)$ .. Only green for pre- market !!!

Jaguar8

Dec 2, 2024 18:05

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

Trytosaveabit

Dec 2, 2024 15:03

Update

$Adaptimmune Therapeutics (ADAP.US)$ First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma

Trytosaveabit

Nov 13, 2024 16:14

Not to shabby!

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...